Presentation is loading. Please wait.

Presentation is loading. Please wait.

Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med.

Published byNoel Banks Modified over 8 years ago

Similar presentations

Presentation on theme: "Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med."— Presentation transcript:

1 Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med. 2012;157(4):251-262. doi:10.7326/0003-4819-157-4-201208210-00005 Grading the quality of CKD subgroups of non-CKD trials. CKD = chronic kidney disease. * Estimated glomerular filtration rate <60 mL/min per 1.73 m 2. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

2 Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med. 2012;157(4):251-262. doi:10.7326/0003-4819-157-4-201208210-00005 Grading the quality of evidence across studies. CKD = chronic kidney disease; RCT = randomized, controlled trial. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

3 Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med. 2012;157(4):251-262. doi:10.7326/0003-4819-157-4-201208210-00005 Summary of evidence search and selection. CKD = chronic kidney disease; RCT = randomized, controlled trial. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

4 Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med. 2012;157(4):251-262. doi:10.7326/0003-4819-157-4-201208210-00005 Random-effects model meta-analyses of RR for all-cause death in patients with CKD receiving lipid-lowering interventions. The summary RRs centered on a combined estimate and extending to 95% CIs for all statins or all interventions versus control (black diamonds) and the summary RR for individual statins versus control (white diamond) are shown. Risk ratios (diamonds) and 95% CIs (horizontal lines) for individual studies also are shown. The size of the squares is proportional to the weight of each study in the overall meta-analysis. Within drug subgroups, studies are ordered by drug dose and sample size. 4D = Die Deutsche Diabetes Dialyse Studie; 4S = Scandinavian Simvastatin Survival Study; ALERT = Assessment of Lescol in Renal Transplantation; AFCAPS/TexCAPS = Air Force Coronary Atherosclerosis Prevention Study/Texas Coronary Atherosclerosis Prevention Study; ALLIANCE = Aggressive Lipid Lowering to Alleviate New Cardiovascular Endpoints; AURORA = A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events; CARE = Cholesterol and Recurrent Events; CARDS = Collaborative Atorvastatin Diabetes Study; CKD = chronic kidney disease; JUPITER = Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin; LIPID = Long-Term Intervention with Pravastatin in Ischemic Disease; LIPS = Lescol Intervention Prevention Study; MEGA = Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; ND = no data; PREVEND IT = Prevention of Renal and Vascular Endstage Disease Intervention Trial; RR = risk ratio; SHARP = Study of Heart and Renal Protection; TNT = Treating to New Targets; UK-HARP-II = Second United Kingdom Heart and Renal Protection; WOSCOPS = West of Scotland Coronary Prevention Study. * Patients with diabetes mellitus. † Patients without diabetes mellitus. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

5 Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med. 2012;157(4):251-262. doi:10.7326/0003-4819-157-4-201208210-00005 Random-effects model meta-analyses of RR in patients with CKD with lipid-lowering interventions for cardiovascular mortality. See legend for Figure 2. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

6 Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med. 2012;157(4):251-262. doi:10.7326/0003-4819-157-4-201208210-00005 Random-effects model meta-analyses of RR in patients with CKD with lipid-lowering interventions for cardiac mortality. See legend for Figure 2. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

7 Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med. 2012;157(4):251-262. doi:10.7326/0003-4819-157-4-201208210-00005 Random-effects model meta-analyses of RR for cardiovascular events, including revascularization, in patients with CKD receiving lipid-lowering interventions. See legend for Figure 2. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

8 Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med. 2012;157(4):251-262. doi:10.7326/0003-4819-157-4-201208210-00005 Random-effects model meta-analyses of RR in patients with CKD with lipid-lowering interventions for cardiovascular events, excluding revascularization. See legend for Figure 2. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

9 Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med. 2012;157(4):251-262. doi:10.7326/0003-4819-157-4-201208210-00005 Random-effects model meta-analyses of RR in patients with CKD with lipid-lowering interventions for myocardial infarction. See legend for Figure 2. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

10 Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med. 2012;157(4):251-262. doi:10.7326/0003-4819-157-4-201208210-00005 Random-effects model meta-analyses of RR in patients with CKD with lipid-lowering interventions for stroke. See legend for Figure 2. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

11 Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med. 2012;157(4):251-262. doi:10.7326/0003-4819-157-4-201208210-00005 Random-effects model meta-analyses of RR in patients with CKD with lipid-lowering interventions for end-stage renal disease. See legend for Figure 2. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

12 Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med. 2012;157(4):251-262. doi:10.7326/0003-4819-157-4-201208210-00005 Random-effects model meta-analyses of RR in patients with CKD with lipid-lowering interventions for end-stage renal disease or worsening kidney function. See legend for Figure 2. eGFR = estimated glomerular filtration rate; ESRD = end-stage renal disease; SCr = serum creatinine. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Download ppt "Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med."

Similar presentations

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
The efFects of Pharmacological management of lipids in patients with CKD Andrew Monson FY1 18/9/14.

The efFects of Pharmacological management of lipids in patients with CKD Andrew Monson FY1 18/9/14.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.

Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 2: Healthy People 2020.

2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 2: Healthy People 2020.
Date of download: 5/28/2016 From: New Fibrate Use and Acute Renal Outcomes in Elderly Adults: A Population-Based Study Ann Intern Med. 2012;156(8):560-569.

Date of download: 5/28/2016 From: New Fibrate Use and Acute Renal Outcomes in Elderly Adults: A Population-Based Study Ann Intern Med. 2012;156(8):
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.
Date of download: 5/28/2016 From: Optimal Timing of Coronary Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Review.

Date of download: 5/28/2016 From: Optimal Timing of Coronary Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Review.
Date of download: 5/29/2016 From: Systematic Review: Comparative Effectiveness and Safety of Premixed Insulin Analogues in Type 2 Diabetes Ann Intern Med.

Date of download: 5/29/2016 From: Systematic Review: Comparative Effectiveness and Safety of Premixed Insulin Analogues in Type 2 Diabetes Ann Intern Med.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Primary Prevention With Statins: ACC/AHA Risk-Based.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Primary Prevention With Statins: ACC/AHA Risk-Based.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Primary Prevention of Cardiovascular Mortality and.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Primary Prevention of Cardiovascular Mortality and.
Date of download: 5/29/2016 From: Statins and Cognitive Function: A Systematic Review Ann Intern Med. 2013;159(10):688-697. doi:10.7326/0003-4819-159-10-201311190-00007.

Date of download: 5/29/2016 From: Statins and Cognitive Function: A Systematic Review Ann Intern Med. 2013;159(10): doi: /
Presentation Title R3 이지영 / 김 수 중교 수 님. Introduction Lowering LDL cholesterol levels with statins : Reduce the risk of cardiovascular disease Vascular.

Presentation Title R3 이지영 / 김 수 중교 수 님. Introduction Lowering LDL cholesterol levels with statins : Reduce the risk of cardiovascular disease Vascular.
Date of download: 5/29/2016 From: The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow- up of the Modification.

Date of download: 5/29/2016 From: The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow- up of the Modification.
Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.
Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Optimal low-density lipoprotein is 50 to 70 mg/dl:

Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Optimal low-density lipoprotein is 50 to 70 mg/dl:
Date of download: 6/2/2016 From: Quantitative Synthesis in Systematic Reviews Ann Intern Med. 1997;127(9):820-826. doi:10.7326/0003-4819-127-9-199711010-00008.

Date of download: 6/2/2016 From: Quantitative Synthesis in Systematic Reviews Ann Intern Med. 1997;127(9): doi: /
Date of download: 6/2/2016 From: Are Metabolically Healthy Overweight and Obesity Benign Conditions?: A Systematic Review and Meta- analysis Ann Intern.

Date of download: 6/2/2016 From: Are Metabolically Healthy Overweight and Obesity Benign Conditions?: A Systematic Review and Meta- analysis Ann Intern.
Date of download: 6/3/2016 From: Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial.

Date of download: 6/3/2016 From: Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial.
Date of download: 6/3/2016 From: Elevated Plasma Homocysteine Level Is an Independent Predictor of Coronary Heart Disease Events in Patients with Type.

Date of download: 6/3/2016 From: Elevated Plasma Homocysteine Level Is an Independent Predictor of Coronary Heart Disease Events in Patients with Type.

Similar presentations

Ads by Google